TAAV Biomanufacturing Solutions, SLU (TAAV), a wholly owned subsidiary of Asklepios Biopharmaceuticals (AskBio) and Bayer AG, is a cGMP manufacturer of neDNA™, an enzymatic DNA material used for adeno associated virus (AAV) gene therapies. neDNA™ is produced using a manufacturing process that eliminates the use...
Landmark Bio translates groundbreaking research into life-changing medicines. We provide development, manufacturing, and regulatory capabilities to help early-stage life science innovators rapidly progress advanced therapies from bench to clinic. Launched in 2021, Landmark Bio is an unprecedented venture bringing together the best of industry, academia...
ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies. ABL's mission is to provide GMP viral vectors from early-stage to market, contributing to the success of its clients'...
Optima Pharma plans, develops and produces filling, closing and process technology for pharmaceutical products requiring the highest cleanliness standards, along with high process reliability and flexibility. Optima Pharma’s extensive turnkey portfolio includes pharmaceutical freeze-drying, isolators, as well as isolated filling equipment and processing isolators for...
Fred Hutchinson Cancer Center (Fred Hutch) is an independent, nonprofit, unified adult cancer care and research center that is clinically integrated with UW Medicine, a world leader in clinical care, research and learning. Fred Hutchinson Cancer Center was created in April 2022 by the merger...
Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry to date. Founded by Feng Zhang, David Walt, David Scott, and Winston Yan, Arbor’s proprietary discovery...
4DMT is a gene therapy company with a transformative discovery platform – Therapeutic Vector Evolution – that enables our “disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease....